5-HT7 receptor antagonist with a potential to treat multiple CNS diseases

What is it about?

Broad pre-clinical evaluation of a novel orally bio-available and safe drug candidate, AVN-101, with high affinity to 5-HT7 receptor and unique capability of facilitated transport into a brain. In animal models, the AVN-101 is effective as anxiolytic, antidpressant,, antiamnesic, and antipsychotic.

Featured Image

Why is it important?

The role of 5-HT6 and 5-HT7 receptors in many CNS diseases such as Schizophrenia, Alzheimer's, general psychosis, neurodegeneration, is being actively pursued in the quest to find more effective and safe drugs. Permeation of the drugs through a blood-brain barrier represents a substantial hurdle for the new small molecule structures. A capability of the AVN-101 to quickly penetrate the barrier and accumulate in the brain against its concentration gradient makes it unique and very promising candidate.